Skip to main content
. 2017 Mar 4;4(2):ofx042. doi: 10.1093/ofid/ofx042

Table 2.

Clinical Presentation and Outcomes of Patients With emm89 and emm1 iGAS Infections in Metropolitan Toronto, 2000–2014

Clinical Presentation/Outcome Clade O
No. (%)
Clade 1
No. (%)
Clade 2
No. (%)
Clade 3
No. (%)
emm89 Total No. (%) emm1 No. (%)
Total 15 (100) 18 (100) 12 (100) 60 (100) 105 (100) 397 (100)
Arthritis 2 (13) 4 (22) 2 (17) 9 (15) 17 (16) 32 (8)c
Bacteremia without focus 0 (0) 3 (17) 3 (25) 7 (12) 13 (12) 61 (15)
Soft Tissue Infection
 Necrotizing fasciitis 0 (0) 0 (0) 0 (0) 2 (3) 2 (2) 36 (9)c
 Other soft tissue 10 (67) 4 (22) 1 (8) 20 (33) 35 (33) 138 (35)
Respiratory Tract Infection
 Lower respiratory 2 (13) 3 (17) 5 (42) 8 (13) 18 (17) 79 (20)
 Upper respiratory 1 (6) 1 (6) 1 (8) 7 (12) 10 (9) 20 (5)
Peripartum infection 0 (0) 1 (6) 0 (0) 4 (7) 5 (5) 8 (2)
Othera 0 (0) 2 (11) 0 (0) 3 (5) 5 (5) 23 (6)
STSS 1 (7) 5 (28) 5 (42) 14 (23) 25 (24) 117 (29)
Case fatalityb 1 (7) 4 (22) 5 (42) 10 (17) 20 (19) 81 (20)
ICU admission 4 (27) 6 (33) 5 (42) 16 (27) 31 (30) 158 (40)

Abbreviations: ICU, intensive care unit; iGAS, invasive group A Streptococcus; STSS, streptococcal toxic shock syndrome.

aOther includes peritoneal infection, gynecological infection not associated with pregnancy.

bCase fatality was defined as death that could be attributed to GAS infection within 30 days of positive culture.

c P < .05 for the comparison with all emm89 patients.